Benefits
Cardiac diastolic function in a small uncontrolled pilot
In a 12-week pilot study, 20 obese prediabetic women took 4 g/day of Calanus oil. Their diastolic filling ratio (E/A) improved from baseline (p = 0.023) and diastolic blood pressure and resting heart rate fell. The study had no placebo group, so the change cannot be attributed to the oil rather than to time or other factors, and the trial was funded by the manufacturer. No independent or placebo-controlled trial has confirmed a cardiac benefit.
Metabolic health in prediabetic populations
In a randomized, placebo-controlled trial, 43 obese adults took 2 g/day of Calanus oil or paraffin placebo for 12 weeks. Fasting insulin, HOMA-IR and a hepatic insulin-resistance index fell significantly, but HbA1c, glucose and insulin during an oral glucose tolerance test, and muscle insulin sensitivity did not change. A larger randomized trial of 266 obese adults with insulin resistance found glucose-homeostasis benefits only in subgroups or when combined with lifestyle changes. Both trials were funded by the manufacturer and reported insulin-resistance indices, not lipid profiles or cytokines.
Sustainable Arctic source with natural astaxanthin
Calanus finmarchicus copepods are the most abundant marine organism on Earth (by biomass), making Calanus® Oil among the most sustainable omega-3 sources available — requiring no fish catch reduction and with a dramatically lower environmental footprint than fish oil. The oil naturally contains a small amount of astaxanthin from the copepod's diet of microalgae, which helps protect the omega-3 fatty acids from oxidation. No human trial of this oil has measured a reduction in inflammation.
Mechanism of action
Wax ester omega-3 delivery and membrane integration
Calanus® Oil wax esters (fatty acid + fatty alcohol ester linkage) require pancreatic lipase and cholesterol esterase for hydrolysis — a different digestive pathway than triglyceride omega-3s. This wax ester absorption pathway may provide more gradual, sustained fatty acid release into circulation compared to rapid triglyceride hydrolysis. Once absorbed, EPA from Calanus® Oil incorporates into cell membrane phospholipids, replacing pro-inflammatory arachidonic acid in immune cell membranes and shifting eicosanoid production toward anti-inflammatory resolvins and protectins rather than inflammatory prostaglandins.
Clinical trials
Single-arm pilot study: 20 obese prediabetic women took 4 g/day of Calanus oil (276 mg EPA plus 256 mg DHA) for 12 weeks, with no placebo group. Cardiac function was assessed by echocardiography and blood pressure by oscillometry. Funded by Zooca Lipids (Calanus AS), Norway.
20 middle-aged obese women with prediabetes.
The diastolic filling ratio (E/A) improved from baseline (p = 0.023), and diastolic blood pressure and resting heart rate fell. Because there was no placebo group, these within-person changes cannot be attributed to the oil. The trial was funded by the manufacturer. Calanus oil delivers omega-3 as wax esters rich in stearidonic acid, with relatively little EPA and DHA per gram, and its human evidence base is far smaller and weaker than that for fish or krill oil.